Medlive Technology Co., Ltd. (2192.HK) Stock

About Medlive Technology Co., Ltd.

Medlive Technology Co., Ltd. operates an online professional physician platform in Mainland China and internationally. The company's precision marketing and corporate solution provides digital marketing, digital detailing, digital marketing consultation, digital content creation, application software development, and other relevant services. Its medical knowledge solution offers medical education and clinical decision support, including licensing software to physicians and other registered users, such as other healthcare professionals and pharmaceutical companies. The company's intelligent patient management solutions include single disease management services, such as disease knowledge dissemination and treatment compliance monitoring; patient education services comprising content development, application software development, and other related services; and chronic disease management services for breast cancer, lung cancer, ovarian cancer, Parkinson's, lymphoma, stroke, and diabetes management. In addition, it is involved in the provision of research and development services; provision of internet hospital services; provision of publication and planning services for medicine guidelines and medical consensus; organizing medical exhibition conferences; provision of medical services; and provision of research services to pharmaceutical companies. The company was formerly known as Kingyee Co., Limited and changed its name to Medlive Technology Co., Ltd. in February 2021. The company was founded in 1996 and is headquartered in Beijing, China.

Medlive Technology Co., Ltd. is led by CEO Liping Tian, employs 724 people, headquartered in Beijing, CN, publicly traded since 2021.

Medlive Technology Co., Ltd. (2192.HK) stock trades at $7.97 with a market capitalization of $5.89B. The stock is valued at a price-to-earnings (P/E) ratio of 15.03, price-to-book of 1.04, price-to-sales of 9.18. Over the past 52 weeks the stock has ranged between $6.31 and $15.38, and currently trades 48.2% below its 52-week high. It pays a dividend yielding 3.64%.

On profitability, Medlive Technology Co., Ltd. generates a return on equity (ROE) of 7.11%, an operating margin of 30.09%, a net profit margin of 52.06%.

Official website: www.medlive.cn